(2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540.
Adrenergic beta-2 Receptor Agonists/adverse effects
(2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243.
(2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997.
(2022). Association between Inhaled β(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. Int J Chron Obstruct Pulmon Dis, 17, 1205-1217. http://doi.org/10.2147/copd.s358927.